Αποτελέσματα αναζήτησης - "метилпреднизолон"

Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 37, № 3 (2022); 144-148 ; Сибирский журнал клинической и экспериментальной медицины; Том 37, № 3 (2022); 144-148 ; 2713-265X ; 2713-2927

Θεματικοί όροι: описание случая, methylprednisolone, pulse therapy, hepatotoxicity, multiple sclerosis, clinical case, метилпреднизолон, пульс-терапия, гепатотоксичность, рассеянный склероз

Περιγραφή αρχείου: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/1516/739; Kuna L., Bozic I., Kizivat T., Bojanic K., Mrso M., Kralj E.et al. Models of Drug Induced Liver Injury (DILI) – Current issues and future perspectives. Curr. Drug Metab. 2018;19(10):830–838. DOI:10.2174/1389200219666180523095355.; Grewal P., Ahmad J. Severe liver injury due to herbal and dietary supplements and the role of liver transplantation. World J. Gastroenterol. 2019;25(46):6704–6712. DOI:10.3748/wjg.v25.i46.6704.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J. Hepatol. 2015;63(4):971–1004. DOI:10.1016/j.jhep.2015.06.030.; Berkovich R.R. Acute multiple sclerosis relapse. Continuum (Minneap Minn.). 2016;22(3):799–814. DOI:10.1212/CON.0000000000000330.; D’Agnolo H.M.A., Drenth J.P.H. High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis: А case report and brief review of literature. Neth. J. Med. 2013;71(4):199–202.; Monteserín L., Jiménez M., Linares P., Rodríguez-Martín L., Álvarez-Cuenllas B., Álvarez-Cañas C. et al. Acute hepatitis secondary to high-dose intravenous methylprednisolone. Gastroenterol. Hepatol. 2018;41(8):508–509. DOI:10.1016/j.gastrohep.2017.09.002.; Oliveira A.T., Lopes S., Cipriano M.A., Sofi a C. Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis. BMJ Case Rep. 2015;2015:bcr2015210722. DOI:10.1136/bcr-2015-210722.; Rotondo E., Graziosi A., Di Stefano V., Mohn A.A. Methylprednisolone-induced hepatotoxicity in a 16-year-old girl with multiple sclerosis. BMJ Case Rep. 2018;11(1):e226687. DOI:10.1136/bcr-2018-226687.; Nociti V., Biolato M., De Fino C., Bianco A., Losavio F.A., Lucchini M. et al. Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Brain Behav. 2018;8(6):e00968. DOI:10.1002/brb3.968.; Zoubek M.E., Pinazo-Bandera J., Ortega-Alonso A., Hernández N., Crespo J., Contreras F. et al. Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. United European Gastroenterol J. 2019;7(6):825–837. DOI:10.1177/2050640619840147.; https://www.sibjcem.ru/jour/article/view/1516

Διαθεσιμότητα: https://www.sibjcem.ru/jour/article/view/1516
https://doi.org/10.29001/2073-8552-2022-37-3-144-148

View record from BASE

5

Academic Journal

The Case of Acute Steroid-Induced Myopathy in the Patient with Autoimmune Thrombocytopenia ; Случай острой стероид-индуцированной миопатии у пациентки с аутоиммунной тромбоцитопенией (клинический слу чай)

Συγγραφείς: N. T. Vatutin, G. A. Ignatenko, G. G. Taradin, I. V. Kanisheva, M. R. Shajmurzin, Н. Т. Ватутин, Г. А. Игнатенко, Г. Г. Тарадин, И. В. Канишева, М. Р. Шаймурзин

Πηγή: The Russian Archives of Internal Medicine; Том 10, № 4 (2020); 314-321 ; Архивъ внутренней медицины; Том 10, № 4 (2020); 314-321 ; 2411-6564 ; 2226-6704

Θεματικοί όροι: лечение, methylprednisolone, glucocorticoids, adverse effects, steroid myopathy, treatment, метилпреднизолон, глюкокортикоиды, побочные эффекты, стероидная миопатия

Περιγραφή αρχείου: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/1077/929; https://www.medarhive.ru/jour/article/view/1077/938; Cushing H. The basophil adenoma of the pituitary body and their clinical manifestation. J Neurosurg. 1932; 21(4): 318-47. doi:10.3171/jns.1964.21.4.0318.; Pivonello R., Isidori A.M., De Martino M.C., et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016; 4(7): 611-29. doi:10.1016/S2213-8587(16)00086-3.; Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013; 17(5): 913-6. doi:10.4103/2230-8210.117215.; Owczarek .J, Jasińska M., Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005 ;57(1): 23-34. PMID: 15849374.; Schakman O, Kalista S., Barbé C., et al. Glucocorticoidinduced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013; 45(10): 2163-72. doi:10.1016/j.biocel.2013.05.036.; Kostyo J.L., Redmond A.F. Role of protein synthesis in the inhibitory action of adrenal steroid hormones on amino acid transport by muscle. Endocrinology. 1966; 79(3): 531–40. doi:10.1210/endo-79-3-531.; Liu Z., Li G., Kimball S.R., et al. Glucocorticoids modulate amino acid-induced translation initiation in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004; 287(2): E275–81. doi:10.1152/ ajpendo.00457.; Hasselgren P.O. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care. 1999; 2(3): 201–5. doi:10.1097/00075197199905000-00002.; Tiao G., Fagan J., Roegner V., et al. Energyubiquitindependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. JCI Insight. 1996; 97(2): 339–48. doi:10.1172/JCI118421.; Bodine S.C., Latres E., Baumhueter S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547): 1704–8. doi:10.1126/science.1065874.; Mitch W.E., Goldberg A.L. Mechanisms of muscle wasting. The role of the ubiquitinproteasome pathway. New Engl J Med. 1996; 335(25): 1897–905. doi:10.1056/NEJM199612193352507.; Combaret L., Adegoke O.A., Bedard N., et al. USP19 is a ubiquitinspecific protease regulated in rat skeletal muscle during catabolic states. Am J Physiol Endocrinol Metab. 2005; 288(4): E693–700. doi:10.1152/ajpendo.00281.2004.; Sacheck J.M., Ohtsuka A., McLary S.C., et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004; 287(4): E591–601. doi:10.1152/ ajpendo.00073.2004.; Yamamoto D., Maki T., Herningtyas E.H., et al. Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve. 2010; 41(6): 819-27. doi:10.1002/mus.21621.; Wang X.H., Zhang L., Mitch W.E., et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem. 2010; 285(28): 21249–57. doi:10.1074/jbc.M109.041707.; Büyükcam F., Calık M., Erkuran M.K., et al. Hypokalemia and muscle paralysis after low-dose methylprednisolone. Am J Emerg Med. 2011; 29(5): 573.e1-2. doi:10.1016/j.ajem.2010.05.00.; Fournier M., Huang Z.S., Li H., et al. Insulin-like growth factor-I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol. 2003; 285(1): R34–43. doi:10.1152/ajpregu.00177.2002.; Shimizu N., Yoshikawa N., Ito N., et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metabolism. 2011; 13(2): 170–82. doi:10.1016/j. cmet.2011.01.001.; Pereira R.M., Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011; 78(1): 41-4. doi:10.1016/j. jbspin.2010.02.025; Полунина А.Г., Исаев Ф.В., Демьянова М.А. Стероидная миопатия (обзор). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012; 10(2): 60-64. PMID: 23250613.; Miller M.L. Glucocorticoid-induced myopathy. Indian J Endocrinol Metab. 2013; 17(5): 913-6. doi:10.4103/2230-8210.117215.; Minetto M.A., Rainoldi A., Jabre J.F. The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies. J. Endocrinol. Invest. 2007; 30(9): 791-6. doi:10.1007/BF03350820.; Minetto M.A., D’Angelo V., Arvat E., et al. Diagnostic work-up in steroid myopathy. Endocrine. 2018; 60(2): 219-23. doi:10.1007/ s12020-017-1472-5.; Mafﬁuletti N.A. Assessment of hip and knee muscle function in orthopaedic practice and research. J. Bone Joint Surg. Am. 2010; 92(1): 220–9. doi:10.2106/JBJS.I.00305.; Bohannon R.W. Measuring knee extensor muscle strength. Am. J. Phys. Med. Rehabil. 2001; 80(1): 13-8. doi:10.1097/00002060200101000-00004.; Baudry S., Lanfranco F., Merletti R., et al. Effects of short-term dexamethasone administration on corticospinal excitability. Med. Sci. Sports Exerc. 2014; 46(4): 695–701. doi:10.1249/ MSS.0000000000000162.; Khaleeli A.A., Edwards R.H., Gohil K., et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983; 18(2): 155-66. doi:10.1111/j.1365-2265.1983.tb03198.; Lovitt S., Marden F.A., Gundogdu B., et al. MRI in myopathy. Neurol. Clin. 2004; 22(3): 509–538. doi:10.1016/j. ncl.2004.03.008.; Zoico E., Corzato F., Bambace C., et al. Myosteatosis and myoﬁbrosis: relationship with aging, inﬂammation and insulin resistance. Arch. Gerontol. Geriatr. 2013; 57(3): 411–6. doi:10.1016/j.archger.2013.06.001.; Lee K., Shin Y., Huh J., et al. Recent issues on body composition imaging for sarcopenia evaluation. Korean J Radiol. 2019; 20(2): 205-17. doi:10.3348/kjr.2018.0479.; Cartwright M.S., Demar S., Grifﬁn L.P., et al. Validity and reliability of nerve and muscle ultrasound. Muscle Nerve. 2013; 47(4): 515–21. doi:10.1002/mus.23621.; Arts I.M., Pillen S., Schelhaas H.J. , et al. Normal values for quantitative muscle ultrasonography in adults. Muscle Nerve. 2010; 41(1): 32-41. doi:10.1002/mus.21458.; Atkinson R.A., Srinivas-Shankar U., Roberts S.A., et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J. Gerontol. A. Biol. Sci. Med. Sci. 2010; 65(11): 1215–9. doi:10.1093/gerona/glq118.; Minetto M.A., Caresio C., Menapace T., et al. Ultrasound-based detection of low muscle mass for diagnosis of sarcopenia in older adults. PM&R. 2016; 8(5): 453–62. doi:10.1016/j. pmrj.2015.09.014.; Minetto M.A., Caresio C., Salvi M., et al. Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing’s disease. J Endocrinol Invest. 2019; 42(7): 757-68. doi:10.1007/s40618-018-0979-9.; Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168-86. doi:10.1182/ blood-2009-06-225565.; Witkowski M., Witkowska M., Robak T. Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. Eur J Haematol. 2019; 103(6): 531-41. doi:10.1111/ejh.13319.; Khan M.A., Larson E. Acute myopathy secondary to oral steroid therapy in a 49-year-old man: a case report. J Med Case Reports. 2011; 5: 82. doi:10.1186/1752-1947-5-82.; Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India. 2003; 51(4): 554-6. PMID: 14742950.; Haran M., Schattner A., Kozak N., et al. Acute steroid myopathy: a highly overlooked entity. QJM. 2018; 111(5): 307-11. doi:10.1093/ qjmed/hcy031.; Liu Y., Chen S., Sun Y., et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. Medicine (Baltimore). 2016; 95(50): e5565. doi:10.1097/MD.0000000000005565.; Buchman A.L. Side effects of corticosteroid therapy. J Clin Gastroenter ol. 2001; 33(4): 289-94. doi:10.1097/00004836200110000-00006.; https://www.medarhive.ru/jour/article/view/1077

Διαθεσιμότητα: https://www.medarhive.ru/jour/article/view/1077
https://doi.org/10.20514/2226-6704-2020-10-4-314-321

View record from BASE

6

Academic Journal

Опыт применения разных схем кортикостероидной терапии эпилептических энцефалопатий у детей. ; Experience of using different schemes corticosteroid therapy for epileptic encephalopathies in children

Συγγραφείς: Kuramshina, D. V., Nekrasova, T. P., Nevmerzhitskaya, K. S., Курамшина, Д. В., Некрасова, Т. П., Невмержицкая, К. С.

Πηγή: Сборник статей

Θεματικοί όροι: EPILEPTIC ENCEPHALOPATHY, DEXAMETHASONE, METHYLPREDNISOLONE, CHILDREN, ЭПИЛЕПТИЧЕСКАЯ ЭНЦЕФАЛОПАТИЯ, МЕТИЛПРЕДНИЗОЛОН, ДЕКСАМЕТАЗОН, ДЕТИ

Περιγραφή αρχείου: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей IV Международной научно-практической конференции молодых учёных и студентов, IV Всероссийского форума медицинских и фармацевтических вузов «За качественное образование», (Екатеринбург, 10-12 апреля 2019): в 3-х т. - Екатеринбург: УГМУ, CD-ROM.; http://elib.usma.ru/handle/usma/4093

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/4093

View record from BASE

7

Academic Journal

Giant cell arteritis. Part III. New trends in its treatment (role of genetically engineered drugs) ; Гигантоклеточный артериит. Часть III. Новые тенденции в лечении (роль генно-инженерных биологических препаратов)

Συγγραφείς: Azamat Makhmudovich Satybaldyev, А. М. Сатыбалдыев

Πηγή: Modern Rheumatology Journal; Том 7, № 1 (2013); 30-33 ; Современная ревматология; Том 7, № 1 (2013); 30-33 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2013-1

Θεματικοί όροι: тоцилизумаб, glucocorticosteroids, methylprednisolone, genetically engineered biological agents, infliximab, etanercept, adalimumab, rituximab, tocilizumab, глюкокортикоиды, метилпреднизолон, генно-инженерные биологические препараты, инфликсимаб, этанерцепт, адалимумаб, ритуксимаб

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/462/440

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/462
https://doi.org/10.14412/1996-7012-2013-2364

View record from BASE

8

Academic Journal

Treatment for rheumatic polymyalgia ; Лечение ревматической полимиалгии

Συγγραφείς: Azamat Makhmudovich Satybaldyev, А. М. Сатыбалдыев

Πηγή: Modern Rheumatology Journal; Том 7, № 1 (2013); 66-72 ; Современная ревматология; Том 7, № 1 (2013); 66-72 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2013-1

Θεματικοί όροι: биологическая терапия, glucocorticosteroids, prednisone, prednisolone, methyl-prednisolone, deflazacort, methotrexate, azathioprine, nonsteroidal anti-inflammatory drugs, biological therapy, глюкокортикоиды, преднизон, преднизолон, метилпреднизолон, дефлазакорт, метотрексат, азатиоприн, нестероидные противовоспалительные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/469/447; Salvarani C., Cantini F., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372(9634):234-45. Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347(4):261—71. Бунчук Н.В. Ревматическая полимиалгия. В кн.: Н.В. Бунчук. Ревматические заболевания пожилых. М.: МЕДпресс-информ, 2010;87—135. Meliconi R., Pulsatelli L., Uguccioni M. et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica: quantitative analysis and influence of corticosteroid treatment. Arthr Rheum 1996;39:1199-207. Salvarani C., Cantini F., Olivieri I. et al. Proximal bursitis in active polymyalgia rheumatica. Ann Int Med 1997;127:27-31. Cantini F., Salvarani C., Olivieri I. et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheum 2001;28:1049-55. Cantini F., Niccoli L., Nannini C. et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheum 2005;23:462-8. Salvarani C., Barozzi L., Cantini F. et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 2008;67:758-61. Gonzalez-Gay M.A., Garcia-Porrua C., Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheum 1998;25:1750-5. Gonzalez-Gay M.A. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthr Rheum 2004;33:289-93. Gonzalez-Gay M.A., Barros S., Lopez-Diaz M.J. et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Baltimore: Medicine, 2005;84:269-76. Maradit-Kremers H., Nicola P.J., Crowson C.S. et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthr Rheum 2005;52:722-32. Warrington K.J., Jarpa E.P., Crowson C.S. et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthr Res Ther 2009;11(2):R50. Barber H.S. Myalgic syndrome with constitutional effect: polymyalgia rheumatic. Ann Rheum Dis 1957;16:207-37. Healey L.A. Long-term follow-up of polymyalgia rheumatica: evidence of synovitis. Semin Arthr Rheum 1984;13:322-8. Bird H.A., Esselinckx W., Dixon A.S. et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979;38(5):434-9. Jones J.G., Hazleman B.L. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981;40(1):1-5. Chuang T.Y., Hunder G.G., Ilstrup D.M., Kurland L.T. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Bird H.A., Leeb B.F., Montecucco C.M. et al. European collaborating PMR group. A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis 2005;64:626-9. Hart F.D. Polymyalgia rheumatica. Br Med J 1969;2(5649):99-100. Hernandez-Rodriguez J., Font C., Garcia-Martinez A. et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients. Baltimore: Medicine, 2007;86(4):233-41. Angeli A., Guglielmi G., Dovio A. et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a crosssectional outpatient study. Bone 2006;39(2):253-9. Hernandez-Rodriguez J., Cid M.C., Lopez-Soto A. et al, Treatment of Polymyalgia Rheumatica. A SystematicReview. Arch Int Med 2009;169(20):1839-50. Caporali R., Cimmino M.A., Ferraccioli G. et al. Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Int Med 2004;141(7):493-500. Salvarani C., Macchioni P., Manzini C. et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Int Med 2007;146(9):631-9. Gonzalez-Gay M.A., Garcia-Porrua C., Vazquez-Caruncho M. et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheum 1999;26(6):1326-32. Narvaez J., Nolla-Sole J.M., Clavaguera M.T. et al. Long-term therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheum 1999;26(9):1945-52. Kremers H.M., Reinalda M.S., Crowson C.S. et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheum 2005;32(1):65—73. Fauchald P., Rygvold O., Oystese B. Temporal arteritis and polymyalgia rheumatica: clinical and biopsy findings. Ann Int Med 1972;77(6):845-52. Gabriel S.E., Sunku J., Salvarani C. et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthr Rheum 1997;40(10):1873-8. Spiera H., Davison S. Long-term follow-up of polymyalgia rheumatica. Mt Sinai J Med 1978;45(2):225-9. Hutchings A., Hollywood J., Lamping D.L. et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthr Rheum 2007;57(5):803-9. Cimmino M.A., Parodi M., Caporali R., Montecucco C. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann NY Acad Sci 2006;1069:315-21. Mowat A.G., Camp A.V. Polymyalgia rheumatica. J Bone Joint Surg Br 1971;53(4):701-10. Delecoeuillerie G., Joly P., Cohen de Lara A., Paolaggi J.B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988;47(9):733-9. Ayoub W.T., Franklin C.M., Torretti D. Polymyalgia rheumatica: duration of therapy and long-term outcome. Am J Med 1985;79(3):309-15. Weyand C.M., Fulbright J.W., Evans J.M. et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Int Med 1999;159(6):577-84. Behn A.R., Perera T., Myles A.B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983;42(4):374-8. Myklebust G., Gran J.T. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis: a prospective two-year study in 273 patients. Scand J Rheum 2001;30(5):260-7. Cimmino M.A., Moggiana G., Montecucco C. et al. Long-term treatment of polymyalgia rheumatic with deflazacort. Ann Rheum Dis 1994;53(5):331—3. Lund B., Egsmose C., Jorgensen S., Krogsgaard M.R. Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int 1987;41(6):316—20. Di Munno O., Imbimbo B., Mazzantini M. et al. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheum1995;22(8):1492-8. Krogsgaard M.R., Lund B., Johnsson B. A long-term prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheum 1995;22(9):1660-2. Dasgupta B., Dolan A.L., Panayi G.S., Fernandes L. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheum 1998;37(2):189—95. Salvarani C., Cantini F., Olivieri I. et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheum 2000;27(6):1470-6. Vander Veen M.J., Dinant H.J., van Booma-Frankfort C. et al. Can methotrexate be used as a steroid-sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55(4):218-23. Caporali R., Cimmino M.A., Ferraccioli G. et al. Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Int Med 2004;141(7):493-500. Ferraccioli G., Salaffi F., De Vita S. et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheum 1996;23(4):624-8. Cimmino M.A., Salvarani C., Macchioni P. et al, Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Longterm follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheum 2008;26(3):395-400. Feinberg H.L., Sherman J.D., Schrepferman C.G. et al. The use of methotrexate in polymyalgia rheumatica. J Rheum 1996;23(9):1550-2. De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45(2):136-8. Salvarani C., Macchioni P., Manzini C. et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Int Med 2007;146(9):631-9. Mowat A.G., Camp A.V. Polymyalgia rheumatica. J Bone Joint Surg Br 1971;53(4):701-10. Littman B.H., Bjarnason D., Bryant G. et al. Steroid-sparing activity of tenidap in patients with polymyalgia rheumatica: a multicenter double-blind randomized placebo-controlled study. J Rheum 1995;22(6):1097-103. Kyle V., Hazleman B.L. Treatment of polymyalgia rheumatica and giant cell arteritis I: steroid regimens in the first two months. Ann Rheum Dis 1989;48(8):658—61. Kyle V., Hazleman B.L. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52(12):847-50. Wegrzyn J., Adeleine P., Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63(10):1232-4. Braun J., Kastner P., Flaxenberg P. et al. MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthr Rheum 2008;58(1):73-81. Kreiner F., Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthr Res Ther 2010;12(5):R176. Braunert L., Bruegel M., Pfrepper C. et al. Rituximab in the treatment of acquired haemophilia A in a patient with polymyalgia rheumatica. Hеmostaseologie 2010;30 (Suppl 1):S40-3. Seitz M., Reichenbach S., Bonel H.M. et al. Rapid induction of remission in large-vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141: 13156. doi:10.4414/smw.2011.13156. Dasgupta B., Salvarani C., Schirmer M. et al. members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheum 2008;35(2):270-7.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/469
https://doi.org/10.14412/1996-7012-2013-2371

View record from BASE

9

Academic Journal

Современные направления в диагностике и лечении осложненной травмы шейного отдела позвоночника и спинного мозга. Обзор литературы

Συγγραφείς: Sibgatulina, D., Safta, R.V., Timirgaz, V.V., Timirgaz, V., Gherman, I.D., Condrea, E.S.

Πηγή: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 38 (2) 171-179

Θεματικοί όροι: травма шейного отдела позвоночника, нейропротекция, трактография, метилпреднизолон, ранняя декомпрессия

Περιγραφή αρχείου: application/pdf

Relation: info:eu-repo/grantAgreement/EC/FP7/1815/EU//; https://ibn.idsi.md/vizualizare_articol/29903; urn:issn:18570011

Διαθεσιμότητα: https://ibn.idsi.md/vizualizare_articol/29903

View record from BASE

10

Academic Journal

ЛЕЧЕНИЕ РЕВМАТИЧЕСКОЙ ПОЛИМИАЛГИИ

Συγγραφείς: Сатыбалдыев, Азамат

Θεματικοί όροι: РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, ГЛЮКОКОРТИКОИДЫ, ПРЕДНИЗОН, ПРЕДНИЗОЛОН, МЕТИЛПРЕДНИЗОЛОН, ДЕФЛАЗАКОРТ, МЕТОТРЕКСАТ, АЗАТИОПРИН, НЕСТЕРОИДНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ, БИОЛОГИЧЕСКАЯ ТЕРАПИЯ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/lechenie-revmaticheskoy-polimialgii
http://cyberleninka.ru/article_covers/14431299.png

View record from BASE

11

Academic Journal

Optimizing the therapy of the erosive and ulcerative form of lichen acuminatus in the mucous coat of the oral cavity ; Оптимизация терапии эрозивно-язвенной формы красного плоского лишая слизистой оболочки полости рта

Συγγραφείς: SEDOVA L.A., PERLAMUTROV Y.N., TERESHCHENKO A.V., OLKHOVSKAYA K.B.

Πηγή: Vestnik dermatologii i venerologii; Vol 88, No 6 (2012); 56-59 ; Вестник дерматологии и венерологии; Vol 88, No 6 (2012); 56-59 ; 2313-6294 ; 0042-4609

Θεματικοί όροι: lichen acuminatus in the mucous coat of the oral cavity, erosive and ulcerative form, anti-oxidant status, Mexidol, prednisolone, красный плоский лишай слизистой оболочки полости рта, эрозивно-язвенная форма, антиоксидантный статус, этилметилгидроксипиридина сукцинат, метилпреднизолон